Pfizer announced on Wednesday that it would begin production of vaccine doses locally at the company’s factory in Dublin (Republic of Ireland) against Kovid-19 as part of a new investment of $ 40 million (.7 32.7 million).
The Dublin facility will produce mRNA material, making it the second plant with similar responsibilities outside the United States. The new multi-million dollar investment is in addition to the company’s 300 million investment plan announced last year for three Irish factories, and plans to create 75 more jobs.
While regulating and securing regulatory approval for vaccine factories is usually a two-year process, the immediate focus on delivering vaccines from Kovid-19 means Pfizer is ready to be operational by the end of this year.
“This is a very important moment for Ireland and for our factory in Dublin. We are very proud to be a part of Pfizer’s Covid-19 vaccine, ”said Paul Duffy, Vice President, Global Distribution, Pfizer.
European regulators are evaluating the Pfizer vaccine for use in young people 12 years of age and older. The company is conducting special experiments on children between the ages of six and 11 on vaccines developed in collaboration with the German company Biotech.
As the European Commission President mentioned earlier this month, the pharmaceutical giant is in talks with the European Union to provide 1.8 billion additional doses to 27 member countries.
Pfizer has significantly increased its vaccine delivery commitment. Initially, it was expected to produce just 1.3 billion doses by 2021. Since then, it has risen to $ 1.7 billion, then to $ 2 billion, and more recently to $ 2.5 billion.